Avulux Patient Feedback: Get Your Patients Back to What They Love
Migraine is a genetic neurological disease that affects nearly 48 million people in the United States — that’s almost 1 in 5 patients in your practice.
Avulux Proudly Partners with Opti-Port and PERC
Avulux is proud to announce formal partnerships with Opti-Port, the eye care industry’s only alliance of growth-oriented, multi-office eye care practices, and with PERC, a collective purchasing organization committed to helping optometric practices boost profitability.
A Neuro-Ophthalmologist’s Perspective On Migraine Prevalence In The Patient Population
Research shows that approximately 80 to 90 percent of patients with migraine report light sensitivity during attacks, and 49 percent report that light sensitivity is their most bothersome symptom during a headache.
Eyenavision And Avulux Introduce Chemistrie Avulux Clips For People Living With Migraine And Light Sensitivity
Eyenavision and Avulux today launched Chemistrie Avulux, an innovative new on-demand eyeglass clip option for people living with migraine and light sensitivity.
Avulux vs. FL-41: What ECPs Need To Know
While FL-41 might have been commonly used in the past, Avulux represents an evolution in precision light filtering technology that offers superior and consistent light filtration for patients living with migraine and light sensitivity.
Brant Southwell Joins Avulux As Chief Commercial Officer
Mr. Southwell will be responsible for leading Avulux’s business-to-business commercial strategy including sales, account management, strategic partnerships, distribution, professional development, and marketing integration.